RxDoctor Payments Data

Daniel Sheehan, MD

Dermatology · Augusta, GANPI 1619088671

Payments from drug & device makers

$10,478in general payments, 2019–2025

Across 481 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$2K
  • Johnson & Johnson$1K
  • Sanofi$946
  • AbbVie$932
  • UCB, Inc.$822
  • Amgen$771
  • plus $4K from 18 others

What the payments were for

  • Food & beverage$9,71093%
  • Education$7687%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,478 in reported general payments places this provider in the 75th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$386,282
Medicare patients
868
Services billed
2,863

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab73$261,846
Cosentyx Sensoready (2 Pens)Secukinumab34$248,967
Dupixent SyringeDupilumab54$201,515
OtezlaApremilast26$140,324
Taltz AutoinjectorIxekizumab12$80,855
Tacrolimus51$6,070
Fluorouracil64$4,506
Ketoconazole276$3,848
Clobetasol Propionate61$2,964
CiclopiroxCiclopirox Olamine65$1,653
Triamcinolone Acetonide114$1,504
Permethrin18$1,171
Metronidazole20$1,130
Desoximetasone14$1,122
Mupirocin71$803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$771$140,32426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 345 dermatology providers in Georgia.

Other dermatology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →